Resistant Pseudomonas aeruginosa Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Resistant Pseudomonas aeruginosa Infections – Pipeline Review, H2 2016’, provides an overview of the Resistant Pseudomonas aeruginosa Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas aeruginosa Infections

The report reviews pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Resistant Pseudomonas aeruginosa Infections therapeutics and enlists all their major and minor projects

The report assesses Resistant Pseudomonas aeruginosa Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas aeruginosa Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas aeruginosa Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc.

AstraZeneca Plc

Biolytics Pharma

CSA Biotechnologies LLC

LegoChem Biosciences, Inc

Melinta Therapeutics, Inc

Phico Therapeutics Limited

Shionogi & Co., Ltd.

Zambon Company S.p.A.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Resistant Pseudomonas aeruginosa Infections Overview 7

Therapeutics Development 8

Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Overview 8

Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis 9

Resistant Pseudomonas aeruginosa Infections - Therapeutics under Development by Companies 10

Resistant Pseudomonas aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 11

Resistant Pseudomonas aeruginosa Infections - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Resistant Pseudomonas aeruginosa Infections - Products under Development by Companies 14

Resistant Pseudomonas aeruginosa Infections - Products under Investigation by Universities/Institutes 16

Resistant Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development 17

Achaogen Inc. 17

AstraZeneca Plc 18

Biolytics Pharma 19

CSA Biotechnologies LLC 20

LegoChem Biosciences, Inc 21

Melinta Therapeutics, Inc 22

Phico Therapeutics Limited 23

Shionogi & Co., Ltd. 24

Zambon Company S.p.A. 25

Resistant Pseudomonas aeruginosa Infections - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

ACHN-975 Prodrug - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CSA-13 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

G-10 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

IMT-504 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

LCB-010200 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

LCB-100200 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

PT-3.33 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

RXP-763 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

RXP-766 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

RXP-770 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

RXP-792 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

RXP-793 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

RXP-808 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

RXP-873 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

S-649266 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules for Resistant Pseudomonas aeruginosa Infections - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

ZP-046 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Resistant Pseudomonas aeruginosa Infections - Dormant Projects 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2 2016 8

Number of Products under Development for Resistant Pseudomonas aeruginosa Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 (Contd..1) 15

Products under Investigation by Universities/Institutes, H2 2016 16

Resistant Pseudomonas aeruginosa Infections – Pipeline by Achaogen Inc., H2 2016 17

Resistant Pseudomonas aeruginosa Infections – Pipeline by AstraZeneca Plc, H2 2016 18

Resistant Pseudomonas aeruginosa Infections – Pipeline by Biolytics Pharma, H2 2016 19

Resistant Pseudomonas aeruginosa Infections – Pipeline by CSA Biotechnologies LLC , H2 2016 20

Resistant Pseudomonas aeruginosa Infections – Pipeline by LegoChem Biosciences, Inc, H2 2016 21

Resistant Pseudomonas aeruginosa Infections – Pipeline by Melinta Therapeutics, Inc, H2 2016 22

Resistant Pseudomonas aeruginosa Infections – Pipeline by Phico Therapeutics Limited, H2 2016 23

Resistant Pseudomonas aeruginosa Infections – Pipeline by Shionogi & Co., Ltd., H2 2016 24

Resistant Pseudomonas aeruginosa Infections – Pipeline by Zambon Company S.p.A., H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Resistant Pseudomonas aeruginosa Infections – Dormant Projects, H2 2016 60

List of Figures

List of Figures

Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2 2016 8

Number of Products under Development for Resistant Pseudomonas aeruginosa Infections – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Targets, H2 2016 27

Number of Products by Stage and Targets, H2 2016 27

Number of Products by Mechanism of Actions, H2 2016 29

Number of Products by Stage and Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Molecule Types, H2 2016 33

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports